Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20260341 | 1.00 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL23052844 | 1.00 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL7475015 | 0.83 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL28260719 | 0.83 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL11715171 | 0.82 | CYP2D6 (0.46) | ALOX5LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL4098441 | 0.82 | SRC (0.52) | ALOX5LMNAHIF1AKDM4ECYP2D6 | |
| SCHEMBL5964063 | 0.81 | KDM4E (0.57) | ALOX5LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL3592244 | 0.81 | KDM4E (0.57) | ALOX5LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL3346793 | 0.81 | KDM4E (0.57) | ALOX5LMNAADRA2AADRA2CHIF1A | |
| SCHEMBL8151796 | 0.81 | KDM4E (0.57) | ALOX5LMNAADRA2AADRA2CHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-1853581-B1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2010-06-02 | — | — | EP | disclosed |
| EP-1853581-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006089798-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | MERCKLE GMBH (DE) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273833-A1 | 2-SULFINYL- AND 2-SULFONYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | ALOX5 1763/4885EPHX1 2459/4885TRPM8 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.